Therapeutic gains have languished behind those achieved for the more common B-cell lymphomas, as few complete and durable responses are achieved with available targeted agents [1, 50, 51, 66–68], particularly among those for which a GATA-3 dependent transcriptional program is oncogenic [2, 5]. Here, GATA3 is linked to B-cell non-Hodgkin lymphoma.